skip to main content

Author: Mark O'Connor

Nouveau Biosciences Recruits Deepthi Damera, Ph.D. to Lead Nanotherapeutics Drug Development

Nouveau Biosciences Recruits Deepthi Damera, Ph.D. to Lead Nanotherapeutics Drug Development

[New York, NY – June 5, 2026] – Nouveau Biosciences is proud to announce the recruitment of Deepthi Damera, Ph.D. to lead its nanochemistry programs at Nouveau Research Technologies, the company laboratory.  Dr. Damera is a highly accomplished biophysicist who has spent the past decade intimately involved in all aspects of nanotechnology, from fabrication to biophysical characterization. […]

Nouveau Biosciences and University of Virginia (UVA) Announce Second Licensing Agreement to Expand the Company’s Unique Pipeline of Innovative Nanomedicines

Nouveau Biosciences and University of Virginia (UVA) Announce Second Licensing Agreement to Expand the Company’s Unique Pipeline of Innovative Nanomedicines

[New York, NY – February, 10, 2026] – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, today announced that it has executed a second Licensing Agreement with the University of Virginia (UVA) to expand the company’s pipeline. The Licensing Agreement ratifies Nouveau’s rights to six additional novel nanomedicine […]

Nouveau Biosciences and CanceRx Announce Letter of Intent to Advance Next-Generation Oncology Therapies

Nouveau Biosciences and CanceRx Announce Letter of Intent to Advance Next-Generation Oncology Therapies

New York, NY and Tampa, FL – January 5, 2026 – Nouveau Biosciences, a biotechnology company pioneering nanomedicines and targeted drug delivery to improve cancer therapeutics, and CanceRx, a purpose-driven funding and development platform focused on advancing innovative oncology treatments through long-duration capital and strategic partnerships, today announced that the two organizations have entered into […]

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies

Nouveau Biosciences and Ardena Enter Agreement to Make Clinical Grade Kromastat, an Innovative Nanomedicine for Early Phase Studies [New York, NY – January 5, 2026] Nouveau Biosciences, a biotechnology company pioneering new approaches to discover novel targeted nanomedicines to improve cancer therapeutics, today announced that it has entered into an agreement with Ardena to manufacture […]